Class Action Lawsuit Filed Against Soleno Therapeutics Over Alleged Misrepresentation of DCCR Safety Data
A class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO), alleging that the company and its officers failed to disclose significant safety concerns related to its drug DCCR during the Class Period from March 26, 2025, to November 4, 2025. The lawsuit claims that the safety risks were not adequately disclosed, potentially affecting the commercial viability of DCCR and leading to investor harm.
Tickers: $SLNO
Topics: class action clinical trial safety concerns DCCR securities fraud Soleno Therapeutics